all report title image
  • Published In : Jan 2023
  • Code : CMI5455
  • Pages : 154
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.

Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.

Market Dynamics

Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.

Key features of the study:

  • This report provides an in-depth analysis of the global glycopeptide antibiotics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global glycopeptide antibiotics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market

Detailed Segmentation:

  • Global Glycopeptide Antibiotics Market, By Drug:
    • Vancocin
    • Orbactiv
    • Dalvance
    • Kimyrsa
    • Others
  • Global Glycopeptide Antibiotics Market, By Disease Indication:
    • Clostridium difficile-associated Diarrhea
    • Endocarditis
    • Skin Structure Infections
    • Others
  • Global Glycopeptide Antibiotics Market, By Distribution Channel:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Glycopeptide Antibiotics Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest Of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • ANI Pharmaceuticals, Inc.*
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Fresenius SE & Co. KGaA
    • Pfizer Inc
    • Mylan N.V.
    • Novartis AG
    • Hikma Pharmaceuticals plc
    • Aurobindo Pharma
    • AbbVie Inc.
    • Melinta Therapeutics, Inc
    • Cumberland Pharmaceuticals Inc
    • Theravance Biopharma
    • Janssen Global Services, LLC
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunities
    • Impact Analysis
    • Key Development Strategies
    • Mergers And Acquisition Scenario
    • Market Trends
    • Brand Analysis
    • Regulatory Scenario
    • PEST Analysis
    • Pricing Analysis
  4. Global Glycopeptide Antibiotics Market – Impact of Coronavirus (Covid-19) Pandemic
    • COVID-19 Epidemiology
    • Impact on Manufacturing
    • Impact on Manufacturing
  5. Global Glycopeptide Antibiotics Market, By Drug, 2017 – 2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017–2030
      • Segment Trends
    • Vancocin
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Orbactiv
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Dalvance
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Kimyrsa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
  6. Global Glycopeptide Antibiotics Market, By Disease Indication, 2017 – 2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017–2030
      • Segment Trends
    • Clostridium difficile-associated Diarrhea
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Endocarditis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Skin Structure Infections
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
  7. Global Glycopeptide Antibiotics Market, By Distribution Channel, 2017 – 2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017–2030
      • Segment Trends
    • Hospital Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Retail Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
    • Online Pharmacy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030, (US$ Mn)
  8. Global Glycopeptide Antibiotics Market, By Region, 2017 – 2030, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
    • North America
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2030, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2017 – 2030, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2030, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Competitive Snapshot
      • ANI Pharmaceuticals, Inc.*
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Fresenius SE & Co. KGaA
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Pfizer Inc
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Mylan N.V.
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Novartis AG
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Hikma Pharmaceuticals plc
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Aurobindo Pharma
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • AbbVie Inc.
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Melinta Therapeutics, Inc
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Cumberland Pharmaceuticals Inc
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Theravance Biopharma
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Janssen Global Services, LLC
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Bristol-Myers Squibb Company
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc.
      • Company Overview
      • Disease Indication Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 18 figures on "Global Glycopeptide Antibiotics Market” - forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

Esomar
Duns
Clutch
DMCA

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo